

## Abstract: PhenX Measures for Tobacco Regulatory Research

PI: Carol Hamilton

3U41HG007050-01S1

The goals of the *PhenX Measures for Tobacco Regulatory Research* Administrative Supplement are to (1) identify additional standard measures related to tobacco regulatory research (TRR) for inclusion in the PhenX Toolkit, and (2) organize these standard measures into collections (Whitehead et al., 2012) of tobacco regulatory measures, including a *Core* collection of measures and up to eight collections of *Specialty* measures. The selection of *Core* and *Specialty* collections will generally follow the process established by the NIDA funded Administrative Supplement: *PhenX Measures for Substance Abuse and Addiction Research*.

The PhenX (consensus measures for **Phen**otypes and **eX**posures) Toolkit provides the scientific community with easy access to a common currency of measures of human phenotypes and exposures. PhenX measures are intended to complement study specific measures and to increase the overall impact of individual studies by making them more amenable to collaborative cross-study analyses. Widespread adoption of Tobacco Regulatory Research (TRR) PhenX measures will facilitate advances in tobacco regulatory science by providing the scientific evidence needed to better inform FDA's regulatory authorities over tobacco products. The TRR collections will also contribute more broadly to the advancement of biomedical, genetic, behavioral, and social sciences research.

The goals of this Administrative Supplement relate to Specific Aim 4 of the *Genomics Resource Grant for PhenX Toolkit* (U41 HG007050).

### Specific Aim 4. Expand Existing and Build New Collaborations

- Collaborate with other groups that are building collections of measures, such as the NIH Toolbox and Patient Reported Outcomes Measurement Information System (PROMIS).
- Collaborate with groups who are collecting data and would benefit from use of standard measures such as the Personal Genome Project (PGP) and the Million Veteran Program (MVP).